Reason for request
Indication extension
Summary of opinion
Favourable opinion for reimbursement in the following indication: “KEYTRUDA, in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), in the treatment of FIGO 2014 Stage III (extension onto the pelvic wall or lower one-third of the vagina and/or causing hydronephrosis or non-functioning kidney) to IVA (involvement of the mucosa of bladder/rectum -adjacent pelvic organ spread-) with or without involvement of the pelvic and/or para-aortic lymph nodes) locally advanced cervical cancer in adults who have not received prior definitive therapy.”
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of KEYTRUDA (pembrolizumab), in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), is substantial in the indication: “in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), in the treatment of FIGO 2014 Stage III (extension onto the pelvic wall or lower one-third of the vagina and/or causing hydronephrosis or non-functioning kidney) to IVA (involvement of the mucosa of bladder/rectum -adjacent pelvic organ spread-) with or without involvement of the pelvic and/or para-aortic lymph nodes) locally advanced cervical cancer in adults who have not received prior definitive therapy.”
|
Clinical Added Value
| moderate |
Considering:
- demonstration in a randomised, double-blind, phase 3 study (KN-A18 trial, including 56.7% FIGO 2014 stage III - IVA patients) of the superiority of pembrolizumab compared to chemoradiotherapy, for the treatment of FIGO stage IB2-IIB and III - IVA locally advanced cervical cancer in adults who have not received prior definitive therapy, in terms of:
- progression-free survival with an HR = 0.70 (95% CI = [0.55; 0.89]; p = 0.002 < the predefined threshold of 0.0172), 7% patients progressed or died in the experimental group versus 29.0% patients in the control group. The median PFS was not reached in either of the two groups.
- overall survival with an HR = 0.67 (95% CI = [0.50; 0.90]; p = 0.0040 < 0.01026), 2% deaths in the experimental group versus 20.5% patients in the control group. The median OS was not reached in either of the two groups.
And despite:
- the absence of any formal conclusion that can be drawn based on the quality of life findings;
- a safety profile deemed to be acceptable compared to chemoradiotherapy but marked by an excess toxicity with grade ≥ 3 AEs reported in 78.3% of patients in the pembrolizumab group and 70.0% of patients in the placebo group). In addition, 20.6% of patients in the pembrolizumab group and 14.9% of patients in the placebo group had an AE resulting in definitive discontinuation of pembrolizumab treatment.
The Committee deems that KEYTRUDA (pembrolizumab) 25 mg/ml, concentrate for solution for infusion, in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), provides a moderate clinical added value (CAV III) compared to chemoradiotherapy.
|
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
ejDuXMQckTWsT2y4